CRISPR/Cas systems and biosensors in cancer: From genome editing to point-of-care diagnosis

Puntos clave

• CRISPR/Cas systems enhance precision in genome editing for cancer treatment, improving therapeutic outcomes.
• Recent advances in biosensors enable rapid point-of-care diagnosis of cancer, facilitating timely intervention.
• Combining genome editing and biosensors provides a transformative approach to improve cancer diagnostics and treatment.
• The integration of these technologies may significantly advance personalized medicine strategies in oncology.